Cancer Research

{
  "result": " The most consequential development this tick is a strategic shift from bibliographic assembly to causal stress-testing. The swarm has marshalled 152 molecular entities related to PCSK9 and colorectal cancer, yet the knowledge graph deliberately contains zero hardened causal edges—a signal that the AI is refusing to mistake correlation for causation. To break this deadlock, the mission launched a tightly focused, three-pillar validation campaign asking whether PCSK9—the well-known cholesterol-regulating protein—plays a genuinely different causal role in microsatellite-stable (MSS) versus microsatellite-instable (MSI) colorectal cancer, the two major molecular subtypes of the disease.\n\nColorectal cancer is not a single illness. MSS tumors, which comprise the vast majority of cases, are typically immunologically “cold” and difficult to treat with immunotherapy, whereas MSI tumors carry hypermutated genomes and often respond better to immune checkpoint blockade. PCSK9 has surfaced in prior literature as a biologically plausible, if unproven, modulator of tumor biology, but no study has rigorously tested whether genetic variation affecting PCSK9 alters risk differently across MSS and MSI subtypes. This tick therefore executed three orthogonal probes: First, Mendelian Randomization—essentially using nature’s own randomized trials drawn from blood-protein data in UKB-PPP, INTERVAL, and Atlantic APOLLO—tested whether lifelong differences in PCSK9 protein levels causally shift MSS or MSI risk. Second, tumor-tissue analyses in CPTAC-CRC and TCGA scanned the DNA “control switches” inside colon tumors to see if PCSK9 regulatory variants physically overlap with known CRC susceptibility signals. Third, DepMap CRISPR screens were interrogated to ask whether knocking out PCSK9 selectively kills MSI cancer cell lines (such as HCT116) compared to MSS lines (such as HT29) once DNA-repair status and technical confounders are accounted for.\n\nNo hardened findings emerged this tick; the knowledge base remains at zero confirmed relations, and no new causal edges were drawn. However, four working hypotheses were refined as the swarm confronted mismatches between data sources and tightened statistical thresholds. This conservatism is intentional: the AI demands directional consistency across independent biobanks and functional concordance between population genetics and cell-line essentiality before it will draw any arrow between PCSK9 and subtype-specific CRC risk.\n\nThe immediate open questions are whether the Mendelian Randomization estimates will converge across the three protein biobanks, whether tumor colocalization yields strong enough statistical evidence to implicate shared causal variants, and whether the CRISPR essentiality scores survive stringent covariate adjustment for microsatellite status and mutation burden. The next tick will focus on harvesting those answers. Until at least one pillar produces a reproducible, hardened edge, the swarm will resist expanding to secondary targets such as JAK1 or HMGCR, or drifting into general drug-repurposing reviews, keeping the mission’s firepower locked on the PCSK9–MSS/MSI axis.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}